C4 Therapeutics (CCCC) executive compensation, 2026 proxy

Andrew J. Hirsch, President & Chief Executive Officer, was paid $2.9M in 2025, down 37% from $4.6M the year before.

Filed
April 29, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.9M-37% vs prior year
CEO pay in equity
53%$1.6M in awards
Prior say-on-pay support
98%of votes cast
CEO 2025 Total Pay
$2,940,975Decreased from prior year total
Say-on-Pay Support
98%Approval at 2025 annual meeting

How Hirsch was paid

$2.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary24%Bonus3%Stock awards24%Option awards29%Non-equity incentive19%All other compensation0%

Named executive officers

ExecutiveTotal
Andrew J. HirschPresident & Chief Executive Officer$2,940,975
Kendra R. AdamsChief Financial Officer$1,476,789
Leonard Reyno, M.D.Chief Medical Officer$1,641,798

What changed and why

  • $2.9MAndrew J. Hirsch received total compensation of $2,940,975 in fiscal 2025, representing a decrease from the prior year total of $4,633,005.
  • Executive compensation programs are heavily weighted toward at-risk pay tied to company performance and objectives.
  • A one-time cash-based award was granted pursuant to the 2020 Plan for eligible executive officers.
  • Stock and option awards represented a significant portion of executive remuneration calculated in accordance with FASB ASC Topic 718.
  • 98%The 2025 say-on-pay advisory vote received over 98% support from stockholders at the annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.